(Total Views: 474)
Posted On: 08/12/2020 11:38:10 AM
Post# of 148903
Highly doubt the trial blood samples belong to anyone other than CYDY. That said, I can see IncellDx being paid to run analysis.
As to "It's easy to understand why viral load was not included, not only is this a M/M cohort that might not show a dramatic increase or decrease in viral load"...I don't find it easy to understand AT ALL.
Whether it's a dramatic increase or not doesn't matter when you know for a fact it already takes whatever viral load is there and reduces it to zero by day 14.
78 patients and "tens of thousands of data points" and they don't collect the mother of all data points full well knowing what's been determined from eIND use?? That's a MAJOR OVERSIGHT in my opinion. In fact, if FDA wants statistics, this would be the top of my list. Plus, viral load is a layup given past data! BP looked like he was saying in a nonverbal manner that he couldn't believe that data wasn't collected.
Major screw up in my opinion...and they aren't doing it for severe/critical? Defies common sense.
As to "It's easy to understand why viral load was not included, not only is this a M/M cohort that might not show a dramatic increase or decrease in viral load"...I don't find it easy to understand AT ALL.
Whether it's a dramatic increase or not doesn't matter when you know for a fact it already takes whatever viral load is there and reduces it to zero by day 14.
78 patients and "tens of thousands of data points" and they don't collect the mother of all data points full well knowing what's been determined from eIND use?? That's a MAJOR OVERSIGHT in my opinion. In fact, if FDA wants statistics, this would be the top of my list. Plus, viral load is a layup given past data! BP looked like he was saying in a nonverbal manner that he couldn't believe that data wasn't collected.
Major screw up in my opinion...and they aren't doing it for severe/critical? Defies common sense.
(3)
(2)Scroll down for more posts ▼
